Department of Medicine I: Endocrinology and Clinical Chemistry, University Hospital Heidelberg, Heidelberg, Germany.
Deutsches Zentrum für Diabetesforschung (DZD) e.V., Munich-Neuherberg, Germany.
PLoS One. 2019 Sep 19;14(9):e0222771. doi: 10.1371/journal.pone.0222771. eCollection 2019.
Asprosin is a counter-regulatory hormone to insulin which plays a role in fasting. It may therefore also play a role in hypoglycaemia unawareness, which has been subsequently examined in this pilot study. Intravenous glucose tolerance test was used to induce controlled hyperglycemia whereas a hyperinsulinemic clamp test was used to induce a controlled hypoglycaemia in 15 patients with diabetes type 1, with and without hypoglycaemia unawareness. Changes in asprosin plasma levels did not differ between patients with and without hypoglycaemia unawareness. However, nine patients with insulin resistance as well as higher liver stiffness values and low-density lipoprotein but lower high-density lipoprotein levels did not show the expected increase in asprosin plasma levels during hypoglycemia. Therefore, insulin resistance and alterations in liver structure, most likely early stages of non-alcoholic fatty liver disease, seem to be relevant in type 1 diabetes and do not only lead to elevated plasma levels of asprosin, but also to a blunted asprosin response in hypoglycemia.
去氨加压素是一种与胰岛素作用相反的激素,在禁食中发挥作用。因此,它也可能在低血糖意识障碍中发挥作用,本研究对此进行了初步探讨。通过静脉葡萄糖耐量试验诱导控制的高血糖,通过高胰岛素钳夹试验诱导 15 例 1 型糖尿病患者的控制低血糖,有无低血糖意识障碍。低血糖意识障碍患者和无低血糖意识障碍患者的去氨加压素血浆水平变化无差异。然而,9 例胰岛素抵抗患者以及更高的肝硬度值、更低的高密度脂蛋白而更低的低密度脂蛋白水平,在低血糖期间并未出现预期的去氨加压素血浆水平升高。因此,胰岛素抵抗和肝结构改变(很可能是非酒精性脂肪性肝病的早期阶段)在 1 型糖尿病中似乎很重要,不仅导致去氨加压素血浆水平升高,而且导致低血糖时去氨加压素反应迟钝。